Budesonide/formoterol adjustable maintenance dosing (AMD) improves health-related quality of life (HRQL) compared with high-dose budesonide (AMD)

W. Pohl, N. Vetter, H. Zwick, W. Hrubos (Grimmenstein, Vienna, Austria)

Source: Annual Congress 2004 - Primary care: asthma treatments
Session: Primary care: asthma treatments
Session type: Thematic Poster Session
Number: 1989
Disease area: Airway diseases

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
W. Pohl, N. Vetter, H. Zwick, W. Hrubos (Grimmenstein, Vienna, Austria). Budesonide/formoterol adjustable maintenance dosing (AMD) improves health-related quality of life (HRQL) compared with high-dose budesonide (AMD). Eur Respir J 2004; 24: Suppl. 48, 1989

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Quality of life of stable dose treatment with salmeterol/fluticasone (SFC) compared with adjustable maintenance dosing (AMD) with formoterol/budesonide (FBC)
Source: Eur Respir J 2005; 26: Suppl. 49, 252s
Year: 2005

Indacaterol once-daily improves health-related quality of life (HRQOL) in COPD patients: a 52-week study
Source: Annual Congress 2009 - New bronchodilators
Year: 2009

NVA237 once daily improves dyspnea and health-related quality of life (HRQoL) in patients with COPD: The GLOW1 trial
Source: Annual Congress 2011 - Bronchodilators in asthma and COPD
Year: 2011


Evaluation of quality of life (QOL) in asthma patients during 6 months formoterol therapy
Source: Eur Respir J 2001; 18: Suppl. 33, 44s
Year: 2001

Tiotropium + olodaterol fixed-dose combination shows clinically meaningful improvements in quality of life versus placebo
Source: International Congress 2015 – New data on established treatments for asthma, COPD and bronchiectasis
Year: 2015


Salmeterol/fluticasone (seretide, S/F) used as needed improves health-related quality of life in asthmatic adolescents uncontrolled with ICS receiving inhaled short-acting β2 agonists (SAB2A)
Source: Eur Respir J 2004; 24: Suppl. 48, 380s
Year: 2004

Indacaterol once-daily improves health-related quality of life in COPD patients: a 26-week comparison with placebo and tiotropium
Source: Annual Congress 2009 - New bronchodilators
Year: 2009

TriOptimize VII: Improvement of health-related quality of life after 3 months treatmentwith extrafine single inhaler triple therapy in COPD patients in a real-world setting.
Source: Virtual Congress 2020 – Clinical studies of COPD: combination inhalers and much more
Year: 2020


Budesonide/formoterol adjustable maintenance dosing (B/F AMD) reduces the burden of asthma more effectively than fixed-dosing (FD) with B/F or salmeterol/fluticasone (S/FL)
Source: Eur Respir J 2004; 24: Suppl. 48, 508s
Year: 2004

Training patients on how to use metered dose inhaler (MDI) by using the 2Tone will improve asthma quality of life (AQOL)
Source: Annual Congress 2008 - Recent advances in the treatment and pathogenesis of pulmonary diseases II
Year: 2008


Paediatric asthma quality of life (PAQLQ) and their parents quality of life (PQLQ) evaluation after budesonide (Pulmicort ®) / uniphyllin treatment of asthmatic children
Source: Eur Respir J 2004; 24: Suppl. 48, 164s
Year: 2004

Benefits of the LAMA/LABA glycopyrronium (GP)/formoterol (FF) MDI FDC, delivered using a novel MDI co-suspension technology (GFF MDI), increase with baseline symptom severity in COPD patients (pts)
Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations
Year: 2016


Adjustable maintenance treatment with budesonide/formoterol combination rapidly improves and maintains quality of life in asthma patients
Source: Eur Respir J 2002; 20: Suppl. 38, 41s
Year: 2002

Salmeterol/fluticasone 50/100 (SFC) dry powder inhaler (DPI) provides improved control and quality of life in patients symptomatic on inhaled corticosteroids (ICS)
Source: Eur Respir J 2002; 20: Suppl. 38, 47s
Year: 2002

Health-related quality of life (HRQL) and use of formoterol in patients with COPD
Source: Eur Respir J 2001; 18: Suppl. 33, 55s
Year: 2001

Adjustable dosing with budesonide/formoterol in a single inhaler maintains improvement in health-related quality of life at a lower drug load than fixed dosing – the ATACO study
Source: Eur Respir J 2003; 22: Suppl. 45, 258s
Year: 2003

Health-related quality of life and asthma control in patients treated with budesonide and formoterol in a single inhaler
Source: Eur Respir J 2001; 18: Suppl. 33, 46s
Year: 2001

Budesonide/formoterol (BUD/FORM) single inhaler therapy (SiT) provides greater overall asthma control than traditional fixed dosing (FD) regimens
Source: Eur Respir J 2004; 24: Suppl. 48, 311s
Year: 2004

A comparative trial of tiotropium, salmeterol and placebo: health-related quality of life
Source: Eur Respir J 2001; 18: Suppl. 33, 26s
Year: 2001

Influence of tiotropium bromide (TB) on the severity of clinical, functional symptoms and health-related quality of life (HRQL) in COPD patients (pts)
Source: Annual Congress 2011 - COPD management
Year: 2011